Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia

We’re pleased to share this press release from Santen, announcing UK approval for Ryjunea. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialization across Europe, the Middle East, and Africa (EMEA).

You can click here to read more about the UK approval which is part of Santen's global effort to address the growing burden of childhood myopia through early, comprehensive care. A PDF copy of the press release is available here.

Shared by Tyler Stowater, board member of Sydnexis, Inc.